Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 60.74% is 51% below its 5-year average of 123.42%, near the low end of its 5-year range (52.79%–404.81%).
As of the fiscal period ended Wednesday, December 31, 2025. 1.37% below its 12-month average of 61.58%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
60.74%
RETURN ON EQUITY (ROE) AVG TTM
61.58%
RETURN ON EQUITY (ROE) AVG 3Y
67.05%
RETURN ON EQUITY (ROE) AVG 5Y
123.42%
RETURN ON EQUITY (ROE) AVG 10Y
136.35%
RETURN ON EQUITY (ROE) AVG 15Y
64.79%
RETURN ON EQUITY (ROE) AVG 20Y
54.50%
CURRENT VS TTM AVG
-1.37%
CURRENT VS 3Y AVG
-9.41%
CURRENT VS 5Y AVG
-50.79%
CURRENT VS 10Y AVG
-55.45%
CURRENT VS 15Y AVG
-6.25%
CURRENT VS 20Y AVG
+11.45%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+457.76%
vs the sector median at left
Novo Nordisk A/S
Market Cap
$209.19B
Return on Equity (ROE)
60.74%
TTM Avg
61.58%
3Y Avg
67.05%
5Y Avg
123.42%
Market Cap
$207.87B
Return on Equity (ROE)
84.87%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
Market Cap
$213.42B
Return on Equity (ROE)
13.24%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$184.11B
Return on Equity (ROE)
10.61%
TTM Avg
20.32%
3Y Avg
18.59%
5Y Avg
17.97%
Market Cap
$161.66B
Return on Equity (ROE)
39.19%
TTM Avg
19.98%
3Y Avg
21.60%
5Y Avg
19.44%
Market Cap
$142.54B
Return on Equity (ROE)
8.31%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$137.13B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$133.37B
Return on Equity (ROE)
41.59%
TTM Avg
-8.30%
3Y Avg
7.76%
5Y Avg
4.45%
Market Cap
$133.25B
Return on Equity (ROE)
3.79%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $209.19B | 60.74% | 61.58% | 67.05% | 123.42% |
| Amgen Inc. (AMGN)vs › | $207.87B | 84.87% | 79.33% | 111.35% | 101.76% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $213.42B | 13.24% | 12.70% | 13.51% | 15.24% |
| Abbott Laboratories (ABT)vs › | $184.11B | 10.61% | 20.32% | 18.59% | 17.97% |
| Gilead Sciences, Inc. (GILD)vs › | $161.66B | 39.19% | 19.98% | 21.60% | 19.44% |
| Pfizer Inc. (PFE)vs › | $142.54B | 8.31% | 9.04% | 13.32% | 16.07% |
| Danaher Corporation (DHR)vs › | $137.13B | 7.61% | 7.38% | 9.51% | 10.24% |
| Bristol-Myers Squibb Company (BMY)vs › | $133.37B | 41.59% | -8.30% | 7.76% | 4.45% |
| CVS Health Corp. (CVS)vs › | $133.25B | 3.79% | 4.23% | 6.35% | 7.74% |
| AstraZeneca PLC (AZN)vs › | $131.47B | 21.95% | 19.16% | 15.60% | 13.86% |
ROE
60.7%
ROA
22.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 52.79% |
| 2024-12-31 | 70.38% |
| 2023-12-31 | 78.53% |
| 2022-12-31 | 66.51% |
| 2021-12-31 | 67.50% |
| 2020-12-31 | 404.81% |
| 2019-12-31 | 450.22% |
| 2018-12-31 | 74.52% |
| 2017-12-31 | 76.54% |
| 2016-12-31 | 83.78% |
| 2015-12-31 | 74.22% |
| 2014-12-31 | 65.72% |
| 2013-12-31 | 59.16% |
| 2012-12-31 | 52.75% |
| 2011-12-31 | 45.66% |
| 2010-12-31 | 38.96% |
| 2009-12-31 | 30.13% |
| 2008-12-31 | 29.24% |
| 2007-12-31 | 26.49% |
| 2006-12-31 | 21.42% |
| 2005-12-31 | 21.22% |
| 2004-12-31 | 18.92% |
| 2003-12-31 | 19.26% |
| 2002-12-31 | 17.87% |
| 2001-12-31 | 19.18% |
| 2000-12-31 | 19.61% |
| 1999-12-31 | 13.03% |
| 1998-12-31 | 13.43% |
| 1997-12-31 | 12.25% |
| 1996-12-31 | 11.26% |
